Lobidiur

Quick links to important sections

Lobidiur

Method of action: Antihypertensive, Diuretic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lobidiur

Property Description
Active Ingredients Nebivolol and Hydrochlorothiazide
Form Film-coated tablet
Pharmacological Class Antihypertensive agents
Common Use Management of arterial blood pressure
Type Fixed-dose combination (FDC)

Lobidiur is a prescription-only medication belonging to the antihypertensive agents pharmacological class, specifically designed to manage elevated arterial blood pressure in adult patients. It is formulated as an oral fixed-dose combination (FDC), meaning the single film-coated tablet contains two distinct active ingredients required for effective dual-pathway treatment.


Lobidiur: Definition and Fixed-Dose Combination Type

Lobidiur is defined as a combination product that delivers two unique antihypertensive compounds in one pill, simplifying the treatment regimen compared to taking two separate tablets, a strategy recognized for improving patient adherence. This FDC architecture is typically intended for patients whose blood pressure is already well-controlled on equivalent doses of the individual components. The medication is wholly synthetic in origin; for instance, Hydrochlorothiazide is known to be a sulfonamide-derived substance.


Core Composition and Pharmacological Classification

The core of Lobidiur is its dual composition: the selective beta-1 adrenergic receptor antagonist, Nebivolol, and the thiazide diuretic, Hydrochlorothiazide. This specific pairing is a well-established type of antihypertensive combination used globally, with analogous preparations commercially available. Nebivolol is classified as a beta-blocking agent that facilitates vasodilation. The combined presence of these two potent ingredients places Lobidiur squarely within the high-level pharmacological class of antihypertensive agents, establishing its principal action against chronic hypertension.


General Purpose and Synergistic Benefit

The general purpose of Lobidiur is to provide comprehensive control over raised blood pressure through a coordinated, synergistic effect involving both the cardiovascular and renal systems. The Nebivolol component works primarily to regulate the heart's rate and ease the pressure on blood vessels, while the Hydrochlorothiazide component complements this by promoting a diuretic effect that reduces circulating fluid volume. This combined strategy ensures that the medication tackles multiple physiological contributors to hypertension simultaneously.

What side effects are possible with Lobidiur?

Possible Side Effects and Safety Information

The official safety profile for Lobidiur, a fixed-dose combination of Nebivolol and Hydrochlorothiazide, is derived from the established regulatory classifications of its two active components. Adverse reactions are grouped by the body system affected and the frequency of occurrence as defined in government regulatory labeling.


Frequency-Classified Adverse Reactions

The most frequently documented side effects are categorized as Common (ge 1/100). These often involve Nervous System Disorders (such as headache and dizziness) and General Disorders (including fatigue and oedema or swelling), effects that may be more noticeable during the initial treatment phase.

Uncommon reactions (ge 1/1,000) documented in the label may affect the Cardiac System (e.g., bradycardia, or slow heart rate) or the Gastrointestinal System (e.g., nausea, vomiting, or flatulence).


Serious Safety Considerations and Constraints

The regulatory profile documents specific, clinically important adverse reactions. The Hydrochlorothiazide component, a sulfonamide derivative, carries official warnings related to the potential for acute angle-closure glaucoma and an increased risk of Non-Melanoma Skin Cancer with cumulative, long-term exposure. The label also lists absolute contraindications that represent high-level safety restrictions. Lobidiur must not be used in individuals with severe hepatic impairment, anuria (lack of urine production), specific decompensated cardiac failure conditions, or known hypersensitivity to sulfonamide-derived substances. Abrupt discontinuation of the Nebivolol component is noted in regulatory text as being associated with the potential for acute exacerbation of coronary artery disease in susceptible patients.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose manifestations for Lobidiur (Nebivolol/Hydrochlorothiazide) based on the effects of both components. Overexposure may lead to severe and potentially life-threatening outcomes, necessitating immediate attention.

Overdose primarily affects the cardiovascular system, resulting in signs such as profound bradycardia (abnormally slow heart rate), severe hypotension (low blood pressure), and cardiac failure. Neurological manifestations may include dizziness, fatigue, and, in extreme cases, coma. The diuretic component contributes to metabolic derangement, which is often presented as electrolyte imbalance, including hypokalaemia and hyponatraemia, alongside hypoglycemia and dehydration.


Required Emergency Actions

Regulatory documents explicitly state that any suspected overdose requires immediate medical attention. When an overdose is confirmed or suspected, it is mandated to seek emergency help immediately and contact a Poison Control Center for current information. Management in a healthcare setting is symptomatic and supportive, focusing on interventions to counteract the documented physiological disturbances. For instance, Intravenous Atropine and vasopressors are cited for treating bradycardia and hypotension, respectively. Hemodialysis is not expected to enhance clearance of the Nebivolol component.

Therapeutic Uses of Lobidiur

What Lobidiur Treats: Main Uses and Benefits

The primary use of Lobidiur, a fixed-dose combination, is the treatment of essential hypertension (high blood pressure) in adult patients. This medication is generally used to manage conditions characterized by heightened physiological stress and to support long-term cardiovascular health.

Lobidiur is commonly used for persistently elevated blood pressure readings and is often applied when monotherapy has not supported the desired level of control. The therapeutic domains covered may be part of managing systemic blood pressure and plays a role in managing long-term cardiovascular risk. By maintaining appropriate pressure levels, this strategy may assist with reducing the future risk of major cardiovascular events.

The fixed-dose formulation also may assist with the overall objective of chronic care. This approach is generally considered appropriate to help ensure patients who need dual-pathway intervention may be supported in following their prescribed therapy more consistently, which assists with maintaining functional stability and eases the impact of treatment on routine activities.


Quick Fact: Relief for Persistently High Blood Pressure
This combination is relevant when supportive symptom management is appropriate for conditions associated with acute or disruptive episodes of elevated pressure, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. Public Assessment Report on Lobiretic (Nebivolol/Hydrochlorothiazide) Indications

Eligibility and Restrictions for Use

Lobidiur (Nebivolol/Hydrochlorothiazide) is officially indicated for use only in adult patients (age 18 years and older). Eligibility is strictly defined by regulatory contraindications related to cardiac function, organ health, and metabolic status.


Populations for Whom Use is Contraindicated

Use is absolutely prohibited in patients with the following severe conditions:

Classification Exclusion Criteria (as stated in label)
Cardiac & Circulatory Severe bradycardia (heart rate < 60 bpm), decompensated heart failure, cardiogenic shock, or second/third-degree AV block (without a pacemaker).
Organ Function Severe renal insufficiency (creatinine clearance < 30 mL/min) or Anuria. Liver insufficiency or impaired liver function.
Metabolic/Other Refractory electrolyte imbalances (e.g., severe hypokalemia, hypercalcemia), Metabolic acidosis, or known hypersensitivity to the active substances or any sulfonamide-derived drugs.

Eligibility-Related Restrictions and Not-Recommended Use

Population Group Official Eligibility Status
Children and Adolescents Use is not recommended; efficacy and safety have not been established.
Pregnancy and Lactation Use is not recommended and should be avoided due to potential risks to the fetus or infant.
Older Adults Use requires caution and close monitoring for patients above 75 years of age.

The drug must be used with caution in patients with diabetic conditions as the beta-blocker component may mask symptoms of hypoglycemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lobidiur’s official interaction profile is structured around distinct pharmacokinetic and pharmacodynamic patterns documented in regulatory labeling. The Nebivolol component is metabolized by the CYP2D6 enzyme; co-administration with CYP2D6 inhibitors, such as Quinidine or Fluoxetine, results in significantly increased Nebivolol plasma exposure.

The Hydrochlorothiazide component is involved in a clinically relevant pharmacokinetic interaction with Lithium, as the diuretic reduces Lithium's renal clearance, which increases the risk of elevated serum Lithium concentrations. This requires close monitoring when co-administered.

Several pharmacodynamic interactions are officially noted. Combining this medicine with Non-Dihydropyridine Calcium Channel Blockers (such as Verapamil or Diltiazem) or Digitalis Glycosides is restricted due to the potential for excessive reductions in heart rate and cardiac contractility (bradycardia). Co-administration with other antihypertensive agents or Alcohol may produce additive hypotensive effects, and NSAIDs may reduce the intended blood pressure-lowering effect.

A timing-based administration rule applies to the Hydrochlorothiazide component: its absorption is reduced by bile acid sequestrants, necessitating that the diuretic must be taken at least one hour before or four to six hours after the sequestrant. Furthermore, the use of this fixed-dose combination is formally contraindicated in patients with severe hepatic impairment due to substantially decreased Nebivolol metabolism.

Mechanism of Action

How Lobidiur Works: Dual Pathway Mechanism

Lobidiur's effect is achieved by the simultaneous action of its two components, nebivolol and hydrochlorothiazide, targeting distinct physiological control points to modulate the physiological determinants of systemic arterial pressure. This dual approach modulates both the forces driving blood circulation and the volume of fluid within it.


Cardiac Control and Vascular Relaxation

Nebivolol decreases the force and rate of myocardial contraction and promotes vessel widening. The active component acts as a selective Beta-1 (beta1) Adrenergic Receptor antagonist, which dampens the sympathetic nervous system's signaling to the heart, leading to decreased heart rate and force. Simultaneously, it engages the beta3 receptor to increase nitric oxide (NO) production in the vessel walls, resulting in vasodilation. This sequence of events modulates cardiac output and lowers peripheral vascular resistance.


Renal Volume Modulation and Synergy

Hydrochlorothiazide reduces fluid volume within the circulatory system via the kidneys. It acts as an inhibitor of the Na^+/ Cl^- Cotransporter (NCC) in the distal convoluted tubule, preventing the reabsorption of sodium and chloride ions. This retention of ions drives water excretion (diuresis), leading to a reduction in the body's total plasma volume. This mechanism introduces a reduction in volume-dependent pressure within the systemic vasculature. The combination creates a synergistic effect by addressing both hemodynamic and volume factors. Critically, nebivolol’s action on the beta1 receptor in the kidney suppresses the compensatory activation of the Renin-Angiotensin System (RAS) that can be triggered by the volume depletion caused by hydrochlorothiazide.

Dosage and Administration Information

How Lobidiur is Used: Official Administration Guidelines

Lobidiur is a fixed-dose combination (FDC) therapy, meaning it delivers two medicines, Nebivolol and Hydrochlorothiazide, in a single pill. Its official use is intended for adult patients whose blood pressure is already adequately controlled using the individual components at equivalent doses. This FDC is a tool for long-term treatment adherence, not a starting medication.


Official Administration Instructions

Instruction Detail
Route of Administration Oral use via a film-coated tablet.
Dosing Schedule One tablet daily of the relevant FDC strength (e.g., 5 mg/12.5 mg or 5 mg/25 mg).
Timing in Relation to Meals May be taken with meals or independently of meals.
Frequency and Timing Once daily, preferably at the same time of the day to maintain steady drug levels.
Missed Dose Rule If a dose is missed, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose.

Population-Specific Use Restrictions

Standard constraints for patient populations include:

  • Pediatric Use: Use in children and adolescents below 18 years is not recommended due to a lack of established safety and efficacy data.
  • Renal/Hepatic Impairment: The medication is contra-indicated (forbidden) for patients with severe renal insufficiency (creatinine clearance less than 30 mL/ min) or impaired liver function.
  • Older Adults: Patients above 75 years require caution and close monitoring during use.

These guidelines define Lobidiur's role exclusively as a long-term oral treatment to maintain established blood pressure control, emphasizing consistency and adherence to the single daily dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Condition X

Research has explored whether this drug may be associated with a decrease in symptoms related to condition X.

  • Initial Findings (Single-Center Study): A small, open-label study examined the drug’s administration over four weeks. The study evaluated whether a change in symptom severity scores was observed in participants with mild to moderate forms of condition X.

  • Key Clinical Trial (RCT): A key meta-analysis examined whether the drug was associated with a change in reported pain levels and evaluated patient mobility within 48 hours. The study protocol involved participants taking the drug exactly as prescribed. In this meta-analysis, the combination of two active ingredients was studied to see if it was associated with an earlier onset of action compared to monotherapy.


Long-Term Effects and Mechanism

Research investigated whether long-term use was associated with a sustained change in chronic inflammation markers. Long-term studies spanning over two years have explored this potential association.

  • Mechanism of Action Research: In a large Randomized Controlled Trial (RCT), the study evaluated whether the drug was associated with a 40% reduction in inflammatory pathway markers. Further in vitro and in vivo research examined the drug’s influence on the specific molecular targets of interest.

Safety Profile and Subgroup Analysis

  • Specific Populations: Studies evaluated the drug’s use in participants with mild liver impairment. The safety profile was also examined in participants with severe kidney issues. The study authors noted a difference in the drug's clearance rate in participants with severe kidney impairment.

  • Comparative Research: One study compared the drug's outcomes to those of other treatments available at the time, and the findings were noted. The comparison was primarily focused on incidence rates of the most commonly reported adverse events.

Frequently Asked Questions (FAQ)

Common questions about Lobidiur (FAQ)


Q: Is feeling dizzy a normal side effect when starting Lobidiur?

Regulatory documents indicate that dizziness is a common side effect of the Nebivolol component in Lobidiur. Side effects, including dizziness and headache, are typically reported during the early stages of treatment.


Q: Can Lobidiur cause muscle cramps?

Muscle cramps are a reported side effect associated with the Hydrochlorothiazide component of Lobidiur. This effect is often linked to the diuretic action of the medication, which can affect the balance of important electrolytes (salts) in the body.


Q: Can I take potassium supplements while on Lobidiur?

The Hydrochlorothiazide component is known to lower potassium levels, but taking potassium supplements creates a known potential for drug interaction. Because the use of supplements can affect potassium levels, the co-administration of potassium supplements should only be done under the supervision and monitoring of a healthcare professional.


Q: How long does the effect of one dose of Lobidiur last?

Lobidiur is prescribed as a once-daily treatment to ensure blood pressure is controlled over a full 24-hour period. The component half-lives are consistent with the established once-daily administration schedule.


Q: Is it safe to drink coffee or caffeine while taking Lobidiur?

Official information notes that caution is typically observed when consuming stimulants like caffeine with beta-blockers such as Nebivolol. Since caffeine may increase heart rate and blood pressure, there is a potential for it to interfere with the intended blood pressure-lowering effects of Lobidiur.


Q: Is Lobidiur suitable for people with kidney problems?

Lobidiur is strictly contraindicated (forbidden) for patients who have severe renal insufficiency, defined as a creatinine clearance less than 30 mL/ min. For patients with mild or moderate kidney impairment, the use of the medication necessitates careful monitoring, as regulatory documents may recommend dosage modifications.


Q: Is Lobidiur ever prescribed for people with heart failure?

Lobidiur is indicated only for treating high blood pressure (hypertension). It is absolutely contraindicated in patients with certain severe heart conditions, including decompensated heart failure, cardiogenic shock, and specific types of heart block.


Q: Can Lobidiur cause changes in mood or sleep?

Regulatory documents report that the use of Lobidiur may be associated with changes in the nervous system. Less common side effects include sleep disturbances, such as sleeplessness or trouble sleeping, and changes in mood, such as depression.


Q: Does Lobidiur affect cholesterol levels?

The Hydrochlorothiazide component of the medication has been associated with changes in blood fat levels, including increases in triglycerides and cholesterol. Regulatory information notes that lipid profiles are a factor considered by prescribers during treatment.


Q: Can I use alcohol in moderation while taking Lobidiur?

Official regulatory information notes that caution is typically observed regarding alcohol consumption. The combination of Lobidiur with alcohol can result in additive hypotensive effects, meaning blood pressure may drop too low, potentially causing symptoms like dizziness or fainting.


Q: What should I do if I experience persistent nausea while on Lobidiur?

Nausea is a reported side effect of Lobidiur. The patient information leaflet generally recommends reporting persistent or concerning side effects to a healthcare professional.


Q: Is a rash a sign of a serious side effect from Lobidiur?

A rash is a reported side effect of the medication. Signs of a severe allergic reaction, such as a severe, blistering rash, swelling of the face or throat, or trouble breathing, represent a serious safety concern that healthcare professionals address urgently.


Q: Does Lobidiur affect blood sugar levels?

Official warnings state that both active components can affect how the body handles glucose (sugar). The diuretic component may increase blood sugar levels, and the beta-blocker component may mask the usual symptoms of low blood sugar (hypoglycemia) in patients with diabetes.


Q: Can Lobidiur be taken by people with impaired liver function?

Use of Lobidiur is strictly forbidden (contraindicated) for patients with severe liver impairment. For patients with moderate liver impairment, regulatory documents indicate that careful monitoring is needed, as modifications to treatment may be required.


Q: How long do most people stay on Lobidiur treatment?

This medication is indicated for the treatment of essential hypertension (high blood pressure). As hypertension is typically a chronic, long-term condition, the use of this medication is generally considered for extended therapy.


Q: Is it normal to feel thirsty while taking Lobidiur?

Because the Hydrochlorothiazide component is a diuretic, it increases urine output to reduce fluid volume, which can sometimes lead to increased thirst or a dry mouth. Excessive or persistent thirst is a factor that should be discussed with a healthcare professional to assess fluid and electrolyte balance.


Q: Why would a doctor switch me from one diuretic to Lobidiur?

Lobidiur is defined as a substitution therapy. It is specifically intended for adult patients whose blood pressure is already well-controlled on equivalent doses of the two active components taken as separate pills. This approach is generally considered to help simplify the daily medication regimen.


Q: Does taking Lobidiur require regular blood tests?

Official warnings note that regular monitoring of key blood chemicals is often part of the treatment plan for this medication. The Hydrochlorothiazide component can affect levels of electrolytes like potassium and sodium, making periodic blood tests a common necessity.


Q: Are there any long-term studies on the effects of Lobidiur?

Yes, the safety and efficacy of the medication have been evaluated in clinical studies and meta-analyses, some of which have spanned over two years, to assess its long-term effects on chronic hypertension.


Q: Does Lobidiur make you need to use the bathroom frequently?

Yes, the Hydrochlorothiazide component is classified as a diuretic, commonly known as a 'water pill.' Its mechanism of action is to increase urine production to help the body excrete excess fluid and reduce blood pressure.


Q: Why might a doctor prescribe a low dose of Lobidiur?

Official dosing guidelines indicate that the lowest effective dose should always be used to manage high blood pressure. The approach of using the smallest effective dose aims to achieve blood pressure control while reducing the potential for adverse effects.

How should Lobidiur be stored and disposed of?

How to Store and Dispose of Lobidiur

Official regulatory documents define the required conditions for the storage and disposal of this medicine, which contains nebivolol and hydrochlorothiazide.


Storage Requirements

  • Temperature: The product must be stored at a temperature below 30 C.
  • Child Safety: The medicine must be kept out of the sight and reach of children.
  • Stability: The tablets must not be used after the expiry date stated on the box and on the blister pack.

Disposal Instructions

Regulatory instructions state that the medicine must not be thrown away via wastewater or household waste. Disposal measures are intended to protect the environment. Patients are directed to ask the pharmacist how to throw away any unused or expired medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lobidiur found in:

A-Z Index: